Description:
This book explores the potential and actual uses of live bacteria or their products in the treatment of cancer. Providing a state-of-the-art overview of the field, this book breaks new ground in emerging cancer treatment modalities. The many microbes that are currently and can potentially be used therapeutically and their products will be reviewed in detail, and studies involving clinical trials, as well as clinical evaluation with these novel anticancer agents will be addressed.
Organized into four sections with fourteen to seventeen chapters, this book begins with a section of chapters detailing the use of live or attenuated bacteria and viruses in the treatment of cancer. The second section covers bacterial products, such as proteins/peptides, toxins, antibiotics, DNA and other products, as anticancer agents. The third section describes an overview about recent and representative patents in the field of bacteria/bacterial products as anticancer agents. Finally, the book addresses the benefits of the emerging multi-targeting approach of a drug (drug promiscuity) in anticancer drug design and discovery.
Table of Contents:
SECTION I Live/attenuated bacteria and viruses as anticancer agents.
Chapter 1: Salmonella typhimurium mutants selected to grow only in tumors and eradicate them in nude mouse models (Robert M. Hoffman).
Chapter 2: The use of living Listeria monocytogenes as an active immunotherapy for the treatment of cancer (John Rothman1, Anu Wallecha1, Paulo Cesar Maciag1, Sandra Riviera, Vafa Shahabi,and Yvonne Paterson).
Chapter 3: Bacillus Calmete-Guerin (BCG) for urothelial carcinoma of the bladder (Timothy P. Kresowik and Thomas S. Griffith).
Chapter 4: Live clostridia: a powerful tool in tumor biotherapy (Lieve Van Mellaert, Ming Q Wei and Jozef Annné).
Chapter 5: Bifidobacterium as a delivery system of functional gene for cancer gene therapy (Geng-Feng Fu, Yan Yin, Bi Hu and Gen-Xing Xu).
Chapter 6: Replication selective viruses for the treatment of cancer (Padma Sampath and Steve H. Thorne).
Chapter 7: Engineering Herpes simplex virus for cancer oncolytic virotherapy (Jason S. Buhrman, Tooba A. Cheema and Giulia Fulci).
SECTION II Bacterial products as anticancer agents.
Proteins/Peptides.
Chapter 8: Promiscuous Anticancer Drugs from Pathogenic Bacteria: Rational versus Intelligent Drug Design (Arsénio M Fialho and Ananda M. Chakrabarty).
Chapter 9: Arginine Deiminase and Cancer Therapy (L. Feun, M.T. Kuo, M. You, C Wu, M. Wangpaichitr and N. Savaraj).
Chapter 10: Cytosine deaminase/5-fluorocytosine molecular cancer chemotherapy (Sergey A. Kaliberov and Donald J. Buchsbaum).
Chapter 11: Bacterial proteins against metastasis (A.M.E.Walenkamp).
Immunotoxins.
Chapter 12: Pseudomonas Exotoxin A based immunotoxins for targeted cancer therapy (Philipp Wolf and Ursula Elsässer-Beile).
Chapter 13: Denileukin Diftitox in Novel Cancer Therapy (Lin-Chi Chen and Nam H. Dang).
Cationic Peptides.
Chapter 14: The Application of Cationic Antimicrobial Peptides in Cancer Treatment: Laboratory Investigations and Clinical Potential (Ashley Hilchie and David W. Hoskin).
Other products.
Chapter 15: Prodiginines and their potential utility as proapoptotic anticancer agents (Neil R. Williamson, Suresh Chawrai, Finian J. Leeper and George P. C. Salmond).
Chapter 16: Farnesyltransferase inhibitors of microbial origins in cancer therapy (Jingxuan Pan and Sai-Ching Jim Yeung).
Chapter 17: The use of RNA and CpG DNA as nucleic acid-based therapeutics (Jörg Vollmer).
SECTION III Patents on bacteria/bacterial products as anticancer agents.
Chapter 18: The Role and Importance of Intellectual Property Generation and Protection in Drug Development (Arsénio M Fialho and Ananda M. Chakrabarty).
|